These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 37724957)

  • 1. Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine.
    Tulyte S; Characiejus D; Matuzeviciene R; Janiulioniene A; Radzevicius M; Jasiunaite E; Zvirblis T; Sileikis A
    Int Immunopharmacol; 2023 Feb; 115():109722. PubMed ID: 37724957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of Treatment on Peripheral Blood Immune Cell Profile in Pancreatic Ductal Adenocarcinoma (PDAC).
    Tulyte S; Characiejus D; Matuzeviciene R; Janiulioniene A; Radzevicius M; Zvirblis T; Sileikis A
    Anticancer Res; 2022 Jun; 42(6):3067-3073. PubMed ID: 35641268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer.
    Liu C; Cheng H; Luo G; Lu Y; Jin K; Guo M; Ni Q; Yu X
    Int J Oncol; 2017 Aug; 51(2):686-694. PubMed ID: 28714519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
    Sams L; Kruger S; Heinemann V; Bararia D; Haebe S; Alig S; Haas M; Zhang D; Westphalen CB; Ormanns S; Metzger P; Werner J; Weigert O; von Bergwelt-Baildon M; Rataj F; Kobold S; Boeck S
    Clin Transl Oncol; 2021 Nov; 23(11):2394-2401. PubMed ID: 33876417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival.
    Xu YF; Lu Y; Cheng H; Shi S; Xu J; Long J; Liu L; Liu C; Yu X
    Pancreatology; 2014; 14(4):295-301. PubMed ID: 25062880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy.
    Murta EF; de Andrade JM; Falcão RP; Bighetti S
    Tumori; 2000; 86(5):403-7. PubMed ID: 11130570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC).
    Xiang ZJ; Hu T; Wang Y; Wang H; Xu L; Cui N
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant Alteration of Circulating Lymphocyte Subsets in Small Cell Lung Cancer Patients Treated with Radiotherapy.
    Li H; Yu H; Lan S; Zhao D; Liu Y; Cheng Y
    Technol Cancer Res Treat; 2021; 20():15330338211039948. PubMed ID: 34851203
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
    Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
    Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial.
    Huffman BM; Basu Mallick A; Horick NK; Wang-Gillam A; Hosein PJ; Morse MA; Beg MS; Murphy JE; Mavroukakis S; Zaki A; Schlechter BL; Sanoff H; Manz C; Wolpin BM; Arlen P; Lacy J; Cleary JM
    JAMA Netw Open; 2023 Jan; 6(1):e2249720. PubMed ID: 36602796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repopulation of circulating T, B and NK lymphocytes following bone marrow and blood stem cell transplantation.
    Parrado A; Casares S; Prieto J; Carmona M; Vaquero A; Rodríguez-Fernández JM
    Hematol Cell Ther; 1997 Dec; 39(6):301-6. PubMed ID: 9497889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system.
    Yang C; Cheng H; Luo G; Lu Y; Guo M; Jin K; Wang Z; Yu X; Liu C
    Eur J Surg Oncol; 2017 Nov; 43(11):2112-2118. PubMed ID: 28802662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotypic Dissection of Normal Peripheral Blood NK Associated (NKa) Subpopulations by Flow Cytometry: Morphological Features and Relationships Between Membrane NKa (CD11b, CD 16, CD56 and CD57) arid T-cell (CD2, CD3, TCR, CD5, CD7, CD8 and CD38) Associated Determinant Expression.
    Richards SJ; Scott CS
    Leuk Lymphoma; 1990; 2(1-2):111-26. PubMed ID: 27456578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel.
    Blomstrand H; Green H; Fredrikson M; Gränsmark E; Björnsson B; Elander NO
    BMC Cancer; 2020 Oct; 20(1):950. PubMed ID: 33008332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma.
    Lohneis P; Sinn M; Bischoff S; Jühling A; Pelzer U; Wislocka L; Bahra M; Sinn BV; Denkert C; Oettle H; Bläker H; Riess H; Jöhrens K; Striefler JK
    Eur J Cancer; 2017 Sep; 83():290-301. PubMed ID: 28772128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models.
    Sakai Y; Miyazawa M; Komura T; Yamada T; Nasti A; Yoshida K; Takabatake H; Yamato M; Yamashita T; Yamashita T; Mizukoshi E; Okuzono M; Ho TTB; Kawaguchi K; Wada T; Honda M; Kaneko S
    Cancer Sci; 2019 Mar; 110(3):903-912. PubMed ID: 30657234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
    Gutierrez-Sainz L; Viñal D; Villamayor J; Martinez-Perez D; Garcia-Cuesta JA; Ghanem I; Custodio A; Feliu J
    Clin Transl Oncol; 2021 Sep; 23(9):1838-1846. PubMed ID: 33866520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis.
    Ramaswamy A; Shah D; Bhargava P; Srinivas S; Kannan S; Shah M; Suman M; Das S; Trikha M; Ostwal V
    Indian J Med Res; 2023 Jan; 157(1):57-65. PubMed ID: 37040228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
    Bellone G; Novarino A; Vizio B; Brondino G; Addeo A; Prati A; Giacobino A; Campra D; Fronda GR; Ciuffreda L
    Int J Oncol; 2009 Jun; 34(6):1701-15. PubMed ID: 19424589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.